111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity

Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively

“…46 These novel techniques include static volume indices and functional LV indices by gated SPECT ERNA and MPI, 27,28 sympathetic neuronal imaging with a wide variety of SPECT and PET tracers, [47][48][49][50][51][52][53][54][55] In-111 antimyosin which is a specific marker of myocyte injury and necrosis, 54,56,57 Tc-99m annexin V which visualized apoptosis and programmed cell death, [58][59][60] fatty acid scintigraphy which visualizes fatty acid retention in the lipid pool of the cytosol which can be impaired by cardiotoxic agents, 61 and direct imaging of In-111 trastuzumab to study trastuzumab targeting of the myocardium have been considered. 62 Each of these techniques would require a prospective clinical trial to assess its incremental value in avoiding clinical CHF. 46 Unfortunately, antimyosin antibody, annexin V, I-123 fatty acids, and In-111 trastuzumab are unavailable for routine clinical use and have limited research availability.…”

“…46 Early uptake of In-111 trastuzumab in anthracycline-exposed patients has been suggested in one preliminary study to identify in a pre-symptomatic stage the presence of early cardiotoxicity. 62 The value of this approach for monitoring patients at risk for trastuzumab induced CHF in anthracycline-pretreated patients remains undefined.…”

Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys

“…39 Although Herceptin-like antibodies were generated by our Her-2/neu vaccines, there was neither inflammatory process nor cardiac dysfunction in all of the immunized monkeys. It might be due to relatively low titers of the specific antibodies or due to the discrepancy in amino-acid sequences between humans and monkeys.…”

Efficacy of Primed In Situ Labelling in Determination of HER-2 Gene Amplification and CEN-17 Status in Breast Cancer Tissue

“…Trastuzumab adjuvant treatment for early HER-2 positive breast cancer is effective for improving patient survival and cost-effectiveness analyses of such treatment have shown acceptable ratios (Fagnani et al, 2007;Garrison et al, 2007;Millar and Millward, 2007;Norum et al, 2007). However, there is a negative aspect to trastuzumab therapy, namely cardiac toxicity (Wolff et al, 2007), which is possibly due to myocardial HER-2 gene over-expression associated with anthracycline treatment (De Korte et al, 2007) and substantial trastuzumab therapy 330 costs.…”